DSpace Repository :: Browsing by Author "Castillo-Passi, Rolando I."

Browsing by Author "Castillo-Passi, Rolando I."

Now showing 1 - 4 of 4

Baseline clinical characterization of participants in the Accelerating Medicines Partnership Schizophrenia Program
(2025) Addington, Jean; Liu, Lu; Chu, Monica; Jungert, Karl; Penzel, Nora; Pasternak, Ofer; Farina, Emily; Carrion, Ricardo E.; Corcoran, Cheryl M.; Mittal, Vijay A.; Strauss, Gregory P.; Yung, Alison R.; Alameda, Luis; Arango, Celso; Borders, Owen; Bouix, Sylvain; Breitborde, Nicholas J. K.; Broome, Matthew R.; Cadenhead, Kristin S.; Castillo-Passi, Rolando I.; Chen, Eric Yu Hai; Choi, Jimmy; Coleman, Michael J.; Conus, Philippe; Diaz-Caneja, Covadonga M.; Ellman, Lauren M.; Fusar Poli, Paolo; Gaspar, Pablo A.; Gerber, Carla; Glenthøj, Louise Birkedal; Horton, Leslie E.; Hui, Christy Lai Ming; Kambeitz, Joseph; Kambeitz-Ilankovic, Lana; Kapur, Tina; Kelly, Sinead; Kerr, Melissa J.; Keshavan, Matcheri S.; Kim, Minah; Kim, Sung-Wan
Background. This paper focuses on the baseline clinical characterization of the participants in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. The AMP SCZ program is designed to investigate a wide array of clinical variables and biomarkers in a total of 2040 clinical high-risk (CHR) participants and 652 community control (CC) participants. Methods. The dataset analyzed includes 1642 individuals at clinical high risk for psychosis and 519 CCs. Key measures include the Positive Symptoms and Diagnostic Criteria for the Comprehensive Assessment of At-Risk Mental States Harmonized with the Structured Interview for Psychosis-Risk Syndromes, which determined CHR criteria and the severity of attenuated psychotic symptoms (APS). Other measures included the Structured Clinical Interview for DSM-5, scales to assess negative symptoms, depression, suicidal ideation, substance use, social and role functioning, and a selection of patient-reported outcomes. Results. CHR participants presented with more severe ratings on all clinical measures and poorer functioning relative to the CC. There were a few significant small associations between measures of APS and other clinical measures. Conclusion. The results from this study support previous research indicating that CHR individuals face serious clinical challenges beyond the risk of developing psychosis. Findings indicate significant associations among various clinical measures, underscoring the complex nature of the CHR population. Limitations are acknowledged, including the preliminary nature of the data and the need for more in-depth analyses from AMP SCZ papers already in progress. Future work will focus on longitudinal data and further exploration of clinical variables and their relationship with biomarkers.
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample
(2025) Allott, Kelly; Yassin, Walid; Alameda, Luis; Billah, Tashrif; Borders, Owen; Buccilli, Kate; Carrión, Ricardo E.; Castillo-Passi, Rolando I.; Cho, Kang Ik K.; Chin, Kota; Coleman, Michael J.; Colton, Beau-Luke; Corral, Sebastián; Dwyer, Dominic; Gundersen, Kristina Ballestad; Gur, Ruben C.; Hoftman, Gil D.; Jacobs, Grace R.; Kelly, Sinead; Lewandowski, Kathryn E.; Marcy, Patricia J.; Matneja, Priya; McLaughlin, Danielle; Nunez, Angela R.; Parsa, Setari; Penzel, Nora; Ray, Susan; Reinen, Jenna M.; Ruparel, Kosha; Sand, Michael S.; Santorelli, Gennarina; Seitz-Holland, Johanna; Spark, Jessica; Tamayo, Zailyn; Thompson, Andrew; Tod, Sophie; Wannan, Cassandra M. J.; Wickham, Alana; Wood, Stephen J.; Zoupou, Eirini
Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairment is considered a core biomarker of schizophrenia. Thus, cognition is a key domain measured in the Accelerating Medicines Partnership® program for Schizophrenia (AMP SCZ initiative). The aim of this paper is to describe the rationale, processes, considerations, and final harmonization of the cognitive battery used in AMP SCZ across the two data collection networks. This battery comprises tests of general intellect and specific cognitive domains. We estimate premorbid intelligence at baseline and measure current intelligence at baseline and 2 years. Eight tests from the Penn Computerized Neurocognitive Battery (PennCNB), which measure verbal learning and memory, sensorimotor ability, attention, emotion recognition, working memory, processing speed, verbal memory, visual memory, and motor speed are administered repeatedly at baseline, and four follow-up timepoints over 2 years. Watch Dr. Kelly Allott and Dr. William S. Stone discuss their work and this article: https://vimeo.com/1023396087.
Sample Ascertainment and recruitment sources in the Accelerating Medicines Partnership Schizophrenia Program
(2025) Addington, Jean; Shalev, Amy; Liu, Lu; Jahraus, Cari; Chu, Monica; Farina, Emily; Fusar Poli, Paolo; Marcy, Patricia J.; Nunez, Angela R.; Calkins, Monica E.; Alameda, Luis; Arango, Celso; Borders, Owen; Bouix, Sylvain; Breitborde, Nicholas J. K.; Broome, Matthew R.; Cadenhead, Kristin S.; Carrion, Ricardo E.; Castillo-Passi, Rolando I.; Chen, Eric Yu Hai; Choi, Jimmy; Coleman, Michael J.; Conus, Philippe; Corcoran, Cheryl M.; Diaz-Caneja, Covadonga M.; Ellman, Lauren M.; Gaspar, Pablo A.; Gerber, Carla; Glenthøj, Louise Birkedal; Horton, Leslie E.; Hui, Christy Lai Ming; Kambeitz, Joseph; Kambeitz-Ilankovic, Lana; Kapur, Tina; Kelly, Sinead; Kerr, Melissa J.; Keshavan, Matcheri S.; Kim, Minah; Kim, Sung-Wan; Koutsouleris, Nikolaos
Background. This paper presents the recruitment sources of clinical high-risk (CHR) and community controls (CC) from the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program, which aims to study various clinical variables and biomarkers in 2040 CHR and 652 CC participants. Methods. A total of 1640 CHR and 514 CC had recruitment source data. The Positive Symptoms and Diagnostic Criteria for the Comprehensive Assessment of At-Risk Mental States Harmonized with the SIPS was utilized to assess CHR criteria and severity of attenuated psychotic symptoms (APSs), and the Global Functioning: Social Scale was used for social functioning. Participants were recruited through various methods, including referrals from healthcare providers, schools, and community agencies, and self-referrals via outreach efforts and advertising. Results. Participants were recruited from 13 different sources, with self-referral being the most common for both CHR and CC. Other notable sources included child and youth services and psychiatric hospitals and departments. Regional differences in recruitment patterns were observed across continents. Differences in age, APS, and social functioning for CHR participants were examined in the top 5 recruitment sources. Overall, self-referred individuals were typically older, with less severe APS and higher levels of functioning, whereas those from adult community mental health services had poorer functioning and more severe APS. The remaining recruitment groups fell between these 2 extremes. Conclusion. This paper highlights the diverse recruitment sources for the AMP SCZ program. Self-referral was a significant source, particularly in North America, reflecting changing help-seeking behaviors influenced by the internet and social media. The findings underscore the importance of understanding recruitment sources to optimize future CHR research.
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures
(2025) Mathalon, Daniel H.; Nicholas, Spero; Roach, Brian J.; Billah, Tashrif; Lavoie, Suzie; Whitford, Thomas; Hamilton, Holly K.; Addamo, Lauren; Anohkin, Andrey; Bekinschtein, Tristan; Belger, Aysenil; Buccilli, Kate; Cahill, John; Carrión, Ricardo E.; Damiani, Stefano; Dzafic, Ilvana; Ebdrup, Bjørn H.; Izyurov, Igor; Jarcho, Johanna; Jenni, Raoul; Jo, Anna; Kerins, Sarah; Lee, Clarice; Martin, Elizabeth A.; Mayol-Troncoso, Rocio; Niznikiewicz, Margaret A.; Parvaz, Muhammad; Pogarell, Oliver; Prieto-Montalvo, Julio; Rabin, Rachel; Roalf, David R.; Rogers, Jack; Salisbury, Dean F.; Shaik, Riaz; Shankman, Stewart; Stevens, Michael C.; Suen, Yi Nam; Swann, Nicole C.; Tang, Xiaochen; Castillo-Passi, Rolando I.
Individuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments. Moreover, given risks of antipsychotic drugs, safer effective medications for CHR individuals are needed. The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program was launched to address this need. Based on past CHR and schizophrenia studies, AMP SCZ assessed electroencephalography (EEG)-based event-related potential (ERP), eventrelated oscillation (ERO), and resting EEG power spectral density (PSD) measures, including mismatch negativity (MMN), auditory and visual P300 to target (P3b) and novel (P3a) stimuli, 40-Hz auditory steady state response, and resting EEG PSD for traditional frequency bands (eyes open/closed). Here, in an interim analysis of AMP SCZ EEG measures, we assess test-retest reliability and stability over sessions (baseline, month-2 follow-up) in CHR (n=654) and community control (CON; n=87) participants. Reliability was calculated as Generalizability (G)-coefficients, and changes over session were assessed with paired t-tests. G-coefficients were generally good to excellent in both groups (CHR: mean =0.72, range=0.49–0.85; CON: mean=0.71, range=0.44–0.89). Measure magnitudes significantly (p < 0.001) decreased over session (MMN, auditory and visual target P3b, visual novel P3a, 40-Hz ASSR) and/or over runs within sessions (MMN, auditory/visual novel P3a and target P3b), consistent with habituation effects. Despite these small systematic habituation effects, test-retest reliabilities of the AMP SCZ EEG-based measures are sufficiently strong to support their use in CHR studies as potential predictors of clinical outcomes, markers of illness progression, and/or target engagement or secondary outcome measures in controlled clinical trials. Watch Dr Daniel H. Mathalon discuss their work and this article: https://vimeo.com/1066564687.

Browsing by Author "Castillo-Passi, Rolando I."

Results Per Page

Sort Options